# Metabolic reprogramming of Alveolar Type 2 cells in response to lung injury

> **NIH NIH R01** · VANDERBILT UNIVERSITY MEDICAL CENTER · 2022 · $608,576

## Abstract

PROJECT SUMMARY
Growing evidence indicates that disrupted mitochondrial function in alveolar epithelial cells and in fibroblasts
can disrupt lung repair. Mitochondrial bioenergetics and metabolism play central roles in stem and progenitor
cell functions in other organs, shifting between mitochondrial respiration and glycolysis to meet the needs of
repair, but have received limited attention in the lung. This proposal will use a rare lung disease as model to
investigate how bioenergetics and metabolism regulate the dynamic events of alveolar epithelial repair.
Hermansky Pudlak syndrome type 1 (HPS-1) patients with mutations in HPS1 exhibit highly penetrant, early
onset, fibrosing interstitial lung disease. We hypothesize that by disrupting mitochondrial networking,
loss of HPS1 impairs mitochondrial respiration, fostering metabolic reprogramming that drives AT2
progenitor cell proliferation at the expense of differentiation, and stimulates pro-fibrotic epithelial-to-
fibroblast signaling. Aim 1 will establish the role of HPS1 in alveolar type 2 (AT2) cell bioenergetics and
metabolism, Aim 2 will determine the impact of HPS1 loss on alveolar epithelial repair, and Aim 3 will identify
how metabolic reprograming in AT2 cells drives fibrotic repair. We will accomplish these studies using robust
MLE15 cell models, primary lung cells from pale ear mice with global inactivation of Hps1, a novel Hps1flox/flox
mouse to examine selective contributions of AT2 cells and fibroblasts to repair in the setting of HPS1 loss,
patient-derived iPS cells with the common HPS1 mutation to provide translational relevance to humans, and
the repetitive bleomycin model to generalize our findings beyond a rare lung disease. The expertise of our
laboratory group coupled with the strength of the pulmonary and mitochondrial communities at Vanderbilt
uniquely position us to successfully execute these experiments. We expect that proposed studies will establish
a role for HPS1 in HPS type 1 lung disease, integrate bioenergetics and metabolism mechanistically into
alveolar repair, and provide insight into AT2 cell bioenergetic failure in a growing number of fibrosing interstitial
lung diseases.

## Key facts

- **NIH application ID:** 10446870
- **Project number:** 1R01HL150617-01A1
- **Recipient organization:** VANDERBILT UNIVERSITY MEDICAL CENTER
- **Principal Investigator:** Susan H. Guttentag
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $608,576
- **Award type:** 1
- **Project period:** 2022-07-01 → 2026-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10446870

## Citation

> US National Institutes of Health, RePORTER application 10446870, Metabolic reprogramming of Alveolar Type 2 cells in response to lung injury (1R01HL150617-01A1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10446870. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*